Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Jul 27 2016

• By Derrick Gingery

FDASignBldg21Entrance_1200x675

Related Content

Biosimilar Market Formation Isn't Going According To Plan

Dec 18 2015

Surge In Applications Triggers User Fee Inflation

Aug 10 2015

Will PDUFA VI Fee Structure Changes Slow Revenue Growth?

Jul 25 2016

FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II

May 12 2016

Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure

May 02 2016

Pending Biosimilars

Mar 07 2016

Biosimilars Program Could 'Explode,' Woodcock Warns Congress

Feb 04 2016

Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed

Jun 20 2016

Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

Jul 20 2016

Additional Topics

United States Drug Review Biosimilars Policy Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.